Concepedia

Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats

Tiantian Ren, Xinxin Yang, Na Wu, Yunpeng Cai, Zhenguo Liu, Weien Yuan

Neuroscience Letters · 2011 · 32 citations · 27 references

Concepts

PharmacyPharmacologyPharmacotherapyControlled Release FormulationsDrug DeliveryNeuropharmacologyControlled Release Oral Dosage FormsControlled Release ProdrugsDrug DispositionDrug Release From Dosage FormsParkinsonian DisordersSustained Release FormulationsDyskinesia ReductionSustained Release ControlSustained-release Capsules

References

27

The rat brain in stereotaxic coordinates

Miklós Palkovits · Neuropeptides · 1983 · 29K citations

Medicine, Neurobiology, Neuroscience +12

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

Manolo Carta, Thomas Carlsson, Deniz Kirik et al. · Brain · 2007 · 622 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1

Hugh C. Hemmings, Paul Greengard, H.Y. Lim Tung et al. · Nature · 1984 · 616 citations

Life Sciences, Neurobiology, Neuroscience +12

L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA

M. Angela Cenci, C. S. Lee, Anders Björklund · European Journal of Neuroscience · 1998 · 614 citations

Life Sciences, Neurobiology, Neuroscience +17

L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

M. Angela Cenci, C. S. Lee, Anders Björklund · European Journal of Neuroscience · 1998 · 542 citations

Medicine, Neurobiology, Neuroscience +17